Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
100 participants
INTERVENTIONAL
2024-09-19
2029-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Assessment of Antibodies and Inflammatory Markers in Postural Tachycardia Syndrome
NCT02196376
Phenotyping of Postural Orthostatic Tachycardia Syndrome (POTS)
NCT06292104
Standing Cognition and Co-morbidities of POTS Evaluation
NCT03602482
Data Collection - Of Syncope Tilt Table Testing Study
NCT03721393
Autoimmune Basis for Postural Tachycardia Syndrome
NCT02725060
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The findings from this study will be an initial first step towards understanding any neurocognitive impairment in participants with long COVID and POTS patients. This is a critical first step to future studies to assess underlying pathophysiology and potential treatments.
Primary hypothesis: Some objective measures of neurocognitive functions will improve in Long COVID and POTS patients after the infusion of 999 mL of normal saline compared to 50mL placebo control.
The primary analysis will compare the standing 5RTI task on the CANTAB testing scores between 999 mL saline infusion and 50 mL saline infusion (placebo).
Study Day and Instrumentation:
* A trained research staff member will insert an intravenous line in the vein of the participant's arm to administer either 999 mL or 50 mL of normal saline, which can take up to 30 minutes.
* After instrumentation, the participant will lie supine for at least 10 minutes while their ECG and BP are continuously recorded.
* The participant will stand up quickly (within several seconds) and then stand quietly for about 11 minutes while the recording continues. The lying-to-stand procedure will allow us to assess the hemodynamics of IST, POTS, and OH. A chair will be provided to the participant at any time they want to sit down during the test.
* After the stand test, the participant will be asked to do the Trail-Making Test (TMT) in the standing position. They will be asked to join numbers and letters in a circle. This test should not take more than approximately 10 minutes. A chair will be provided if they want to sit down at any time during the test.
* The participant will then be seated comfortably in a chair with their feet on the floor. They will be asked to do the Heart Counting Task (HCT) test. The participant will be asked to count their heartbeats without using their hands or other means to feel their pulse, which might affect their performance. This test will take approximately 10 minutes.
* The research team will then de-instrument the participant except for the Blood Pressure cuff on the arm. The team will continue to monitor the blood pressure throughout the study.
* Neuropsychological testing of the cognitive domains of memory, attention and executive function will be assessed using the Cambridge Neuropsychological Test Automated Battery (CANTAB) both seated and standing.
* The seated cognitive testing period will last approximately 60 minutes.
* The participant will be asked to stand unaided for up to 30 minutes and repeat portions of the CANTAB tests. Blood Pressure will be monitored throughout the stand test. A chair will be provided to the participant in case they would want to sit down.
* At the end of each stand test, the investigators will assess the patient's symptoms using the Vanderbilt Orthostatic Symptoms Score (VOSS). VOSS is a 9-item symptom rating, with each item scoring from 0 (absent) to 10 (worst) for a total score ranging from 0 to 90.
* The study will then be finished. The investigators will remove the recording patches and electrodes.
* The participant will then be booked for the second visit according to their convenience, where all the tests will be repeated, including IV insertion and infusion of normal saline, supine, and stand, and the cognitive tests (CANTAB, TMT, and HCT). Repeating these tests will help the research team assess whether the cognitive functions will improve for the Long COVID and POTS patients with blood volume expansion with the infusion of normal saline.
CANTAB Testing Protocol: CANTAB tests have demonstrated sensitivity to detecting changes in neuropsychological performance and include tests of working memory, learning and executive function; visual, verbal and episodic memory; attention, information processing and reaction time; social and emotion recognition, decision making and response control. The subtests that will be used in this study for seated cognitive function are: Reaction Time Test (psychomotor Speed), Rapid Visual Information processing (Attention), Paired Associates Learning (Visual Episodic Memory), Spatial Span (Working memory), Verbal Recognition Memory (Verbal memory), Multitasking Test (Executive Function - Inhibition), Stocking of Cambridge (Executive Function - Planning) and the Emotional Bias Task (Emotion Processing). All tests are administered using a touchscreen tablet, and participants will respond to each test on-screen. Standardized written and audio instructions are given to participants through the software, and practice trials are completed before each test, reducing practice effects. Seated testing will be completed in approximately 60 minutes. The Reaction Time Test, Rapid Visual Processing and Multi Tasking tests will be repeated upon standing and will take approximately 30 minutes to complete.
After the in-lab portion of the study, participants will complete a series of validated questionnaires through a paper or RedCap secure web application for assessment of psychiatric symptoms. A unique URL link will be sent to the participants via Redcap Survey. These online surveys will take approximately 60 minutes to complete.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
999 mL normal Saline
999 mL of normal saline infused intravenously.
IV normal saline (999 mL infusion)
999 mL of IV normal saline will be infused intravenously
50 mL normal Saline
50 mL of normal saline infused intravenously.
IV normal saline (50 mL infusion)
50 mL of IV normal saline will be infused intravenously as a placebo control.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
IV normal saline (999 mL infusion)
999 mL of IV normal saline will be infused intravenously
IV normal saline (50 mL infusion)
50 mL of IV normal saline will be infused intravenously as a placebo control.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* SARS-COV2 test positive
* Symptoms \> 12 weeks post COVID
* Subjective complaint of 'brain fog" or cognitive dysfunction
* Patients with diagnosis of Postural Orthostatic Syndrome (POTS) from the Calgary Autonomic Investigation and Management Clinic
* Subjective complaint of 'brain fog" or cognitive impairment
* Healthy participants
* Without POTS or "brain fog"
* Age 18 to 60 years
* Female and Male
* Able to give an informed consent
Exclusion Criteria
* An inability to safely withdraw from medicine(s) that could make test interpretation difficult and impossible.
* Other factors which are in the investigator's opinion would prevent the participant from completing the protocol, including poor compliance during previous studies or an unpredictable schedule.
* Unable to give an informed consent.
18 Years
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Calgary
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Satish R Raj, MD MSCI
Role: PRINCIPAL_INVESTIGATOR
University of Calgary
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Calgary
Calgary, Alberta, Canada
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
REB23-0202
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.